Connect with us

Finance

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

Published

on

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

LOS ANGELES, Aug. 15, 2024 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company“), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced the appointment of life sciences accounting and finance veteran David House as Senior Vice President, Finance, effective August 16th. Armata’s Corporate Controller, Richard Rychlik, will retain the position of Controller.

“We are delighted to welcome David to the Armata team,” stated Dr. Deborah Birx, Chief Executive Officer of Armata. “David’s extensive experience and track record of serving in senior accounting and finance roles within both clinical and commercial stage life sciences companies will serve us well as we continue to advance our two distinct programs – AP-PA02 and AP-SA02 – and prepare to initiate pivotal studies next year. This is an exciting time at Armata, and the addition of David to our senior team helps ensure that we are best positioned to achieve long-term success as we work to introduce an exciting new class of anti-infectives to treat serious drug-resistant bacterial infections.”  

Before joining Armata, Mr. House served as Corporate Controller and Vice President of Accounting at ZO Skin Health, Inc., a multi-channel physician-dispensed skincare company, from October 2018 to May 2024. At ZO Skin Health, he led global accounting operations, managed financial reporting, and played a crucial role in the company’s acquisition by Blackstone. He also established international subsidiaries and oversaw financial integration for mergers and acquisitions. Mr. House’s experience includes similar financial leadership roles at Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, and Avid Bioservices, Inc. (CDMO), a contract development and manufacturing organization where he served as Controller and was responsible for implementing ASC 606, managing technical accounting, and conducting Securities and Exchange Commission (the “SEC“) reporting.

Mr. House’s career also includes roles at Viant, Inc. (DSP), Sourcing Solutions, LLC, and Apria Healthcare (APR), where he held various accounting and financial management positions. In the early stages of his career, Mr. House worked as a Senior Auditor at Windes, a public accounting firm. There, he managed comprehensive audits for public, private, and not-for-profit entities and contributed to SEC filings and internal control evaluations. Mr. House holds a Bachelor of Arts in Business Administration with an Accounting concentration from California State University, Fullerton. He obtained his California Certified Public Accountant license, which is currently inactive.

About Armata Pharmaceuticals, Inc.

Advertisement

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.

Forward Looking Statements

This communication contains “forward-looking” statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata’s future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata’s actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions. These forward-looking statements reflect management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata’s development of bacteriophage-based therapies; ability to staff and maintain its production facilities under fully compliant current Good Manufacturing Practices; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata’s estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption “Risk Factors” and elsewhere in Armata’s filings and reports with the SEC, including in Armata’s Annual Report on Form 10-K, filed with the SEC on March 21, 2024, and in its subsequent filings with the SEC.

Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Media Contacts:

Advertisement

At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
[email protected]
310-665-2928 x234

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
[email protected]
212-915-2569

SOURCE Armata Pharmaceuticals, Inc.

Finance

Equities are using labor data ‘as an excuse,’ strategist says

Published

on

Equities are using labor data ‘as an excuse,’ strategist says

Stocks closed Friday’s session lower, with the Dow Jones Industrial Average (^DJI) and Nasdaq Composite (^IXIC) both shedding over 1.6% following the better-than-expected December jobs report. Wall Street experts are looking at the fresh employment data as a cause for the Federal Reserve to slow its interest rate cuts originally planned for 2025.

Glenmede Chief of Investment Strategy and Research Jason Pride shares his thoughts with Julie Hyman and Josh Lipton on the report, calling it “pretty decent” and believes the market could be using the labor print “as an excuse.”

“And to have some excuses for taking a breather is reasonable. That the market’s pointing to this one. I don’t know that this is really the long-term story here,” Pride explains. “In fact, quite often, we believe that markets with interest rates, with inflation expectations, they quite often take the most recent data points and actually extrapolate them a little bit too far.”

Pride also emphasizes the importance of broadening out and rebalancing one’s portfolio in order to explore more of the opportunities — from small-cap stocks (^RUT) to fixed-income (^TYX, ^TNX, ^FVX) — 2025 has to offer.

“Take your eyes a little bit off of the big [Magnficient] Seven or [the] big cap growth stocks that everybody is so focused on. Take your eyes a little bit off of that and recognize there is an entire investment universe to own,” Pride says.

Advertisement

To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.

This post was written by Josh Lynch

Continue Reading

Finance

US labor market finishes 2024 on high note, adding 256,000 jobs in December as unemployment falls to 4.1%

Published

on

US labor market finishes 2024 on high note, adding 256,000 jobs in December as unemployment falls to 4.1%

The US economy added more jobs than forecast in December while the unemployment rate unexpectedly fell.

Data from the Bureau of Labor Statistics released Friday showed 256,000 new jobs were created in December, far more than the 165,000 expected by economists and higher than the 212,000 seen in November. The unemployment rate fell to 4.1% from 4.2% in November. December marked the most monthly job gains seen since March 2023.

Revisions to the unemployment rate in 2024 also showed the labor market was stronger than initially thought. The cycle high for the unemployment rate had initially been 4.3% in July but that figure was revised down to 4.2% in Friday’s release.

“There is no denying that this is a strong report,” Jefferies US economist Thomas Simons wrote in a note to clients on Friday.

Wage growth, an important measure for gauging inflation pressures, rose 0.3% in December, in line with economists’ expectations and below the 0.4% seen in November.

Advertisement

Compared to the prior year, wages rose 3.9% in December, below the 4% seen in November. Meanwhile, the labor force participation rate was flat at 62.5%.

The strong picture of the US labor market presented in Friday’s report pushed out investor bets on when the Federal Reserve will cut interest rates next. Traders now see a less than 50% chance of the Fed cutting interest rates until June, per the CME Fed Watch Tool. A day prior, investors had favored a cut in May.

Read more: How the Fed rate cut affects your bank accounts, loans, credit cards, and investments

“You’re seeing this steady but slightly cooling labor market trend, which is very encouraging from a Fed perspective,” EY chief economist Gregory Daco told Yahoo Finance. “I think the attention will actually pivot back towards inflation developments over the course of the next three months.”

Stocks sank following the report, with futures tied to all three major averages down nearly 1%. Meanwhile, the 10-year Treasury yield (^TNX), a recent headwind for stocks, added about 8 basis points to reach 4.78%, its highest level since November 2023.

Advertisement

“The problem here now is if you’re looking for rate cuts based on a weakening labor market..stop looking for those,” Steve Sosnick, chief strategist at Interactive Brokers, told Yahoo Finance. “It’s not going to happen in the immediate term.”

A general view as fans hold up national flags in support of Team United States during the evening Swimming session on day eight of the Olympic Games Paris 2024 at Paris La Defense Arena on Aug. 3, 2024, in Nanterre, France. (Quinn Rooney/Getty Images) · Quinn Rooney via Getty Images

Josh Schafer is a reporter for Yahoo Finance. Follow him on X @_joshschafer.

Click here for the latest stock market news and in-depth analysis, including events that move stocks

Read the latest financial and business news from Yahoo Finance

Advertisement

Continue Reading

Finance

SBA Offers Financial Relief to Los Angeles County Businesses and Residents Impacted by Devastating Wildfires

Published

on

SBA Offers Financial Relief to Los Angeles County Businesses and Residents Impacted by Devastating Wildfires

Administrator Guzman to Travel to Southern California to Assess Needs

WASHINGTON, Jan. 09, 2025 (GLOBE NEWSWIRE) — Today, SBA Administrator Isabel Casillas Guzman announced that low-interest federal disaster loans are now available to Southern California businesses, homeowners, renters and private nonprofit (PNP) organizations following President Joe Biden’s major disaster declaration. The declaration covers Los Angeles and the contiguous counties of Kern, Orange, San Bernardino, and Ventura due to wildfires and straight-line winds that began Jan. 7, 2025.

Administrator Guzman also will join FEMA Administrator Deanne Criswell in Southern California this week to assess on-the-ground needs and ensure the SBA is fully prepared to assist businesses, homeowners, and renters impacted by this disaster.

“As heroic firefighters and first responders continue to battle the devastating wildfires sweeping across Southern California, the federal government is surging resources to ensure that Angelenos are prepared to recover and rebuild from this catastrophe,” said SBA Administrator Guzman. “In response to President Biden’s major disaster declaration, the SBA is mobilizing to provide financial relief to impacted businesses and residents. Our continued prayers are with the brave individuals working to put out these fires as well as all those who have lost loved ones, their homes, and their businesses to this disaster. We stand ready to support our fellow Americans for as long as it takes.”

Loans are available to businesses of all sizes and PNP organizations to repair or replace damaged or destroyed real estate, machinery, equipment, inventory, and other business assets. The SBA also offers Economic Injury Disaster Loans (EIDLs) to small businesses, small agricultural cooperatives, small businesses engaged in aquaculture, and most PNP organizations to help meet working capital needs caused by the disaster, even if there is no physical damage. EIDLs may be used to pay fixed debts, payroll, accounts payable, and other expenses that would have been met if not for the disaster. Businesses can apply for loans of up to $2 million.

Advertisement

Disaster loans of up to $500,000 are available to homeowners to repair or replace damaged or destroyed real estate. Homeowners and renters also are eligible for up to $100,000 to repair or replace damaged or destroyed personal property, including personal vehicles.

Interest rates can be as low as 4% for businesses, 3.625% for PNP organizations, and 2.563% for homeowners and renters, with terms up to 30 years. Loan amounts and terms are set by the SBA and based on each applicant’s financial condition. Interest does not begin to accrue until 12 months from the date of the first disaster loan disbursement and loan repayment can be deferred 12 months from the date of the first disbursement.

Advertisement
Continue Reading

Trending